Lantern Pharma cleared to expand lung cancer treatment trial
US-based biopharmaceutical company Lantern Pharma has received regulatory approval for expanding its Phase II Harmonic clinical trial of an investigational new drug, LP-300, for treating non-small cell lung cancer (NSCLC). The multicentre, open-label trial …